Rashi Peripherals Ltd
RPTECHRashi Peripherals Ltd's price has outrun its earnings. +183.1% in a year against EPS +33.4% — the market is paying now for delivery later.
The sharpest disagreement: profits are rising, but only −45% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (47 weeks in) while the P/E sits at the 93rd percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +69.4% year on year, and −45% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Rashi Peripherals Ltd trades at ₹893, in a confirmed uptrend and 47 weeks into that stage. That is +45.7% against its own 200-day average. It sits at 100% of a 52-week range of ₹325 to ₹895. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 60 straight weeks.
Today the stock is in a confirmed uptrend — week 47 of stage 2, confirmed. At ₹893 it trades +45.7% versus its 200-day average and sits at 100% of its 52-week range (₹325–₹895).
Against the market, two honest reads. Cumulative: over the last 2.6 years the stock moved +158% while the NIFTY 500 moved +12% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 60 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Rashi Peripherals Ltd trades at 18.6× P/E, at the pricey end of its own range (93rd percentile). Its long-run median P/E is 10.8×, measured across 2.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 18.6× is at the pricey end of its own range (93rd percentile), against a long-run median of 10.8× measured over 2.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +33.4% against a +183.1% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources disagree by up to 17% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Rashi Peripherals Ltd was paying for profit growth of about 4.2% a year. Profit itself has compounded 38.4% a year over the past 7 years. Today the market pays 18.6× P/E, the 93rd percentile of its own 2-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 25 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Rashi Peripherals Ltd reads as consistent on its fundamental arc. Consistent — revenue and profit growth have stayed positive through the window, with ROCE at 17.0% and holding. The read is built from 8 quarters across 3 curves, on partial evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +14.9% | +18.7% | +21.7% | — |
| Profit | +34.3% | +31.9% | +15.7% | — |
| EPS | +33.4% | — | — | — |
| Share price | +183.1% | — | — | — |
4-Factor Sector Score
63.3/100 — rank 4 of 58 in Trading · 75% evidence confidence
Rashi Peripherals Ltd scores 63.3 out of 100 against the 58 companies it is compared with in Trading, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 24.3 + 14.7 + 10.6 + 13.7 = 63.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Rashi Peripherals Ltd reported ₹5,102 Cr of revenue in the Jun 26 quarter, +61.9% year on year. That is the 4th straight quarter of year-on-year growth. Over 7 years it has compounded at 21.8% a year. The last full year, FY26, came in at ₹15,827 Cr. The last four reported quarters add to ₹17,776 Cr.
FY26 revenue came in at ₹15,827 Cr (+14.9% on the year), capping 7 years at 21.8% compound. The latest quarter (Jun 26) printed ₹5,102 Cr, +61.9% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +41.9% growth against the decade's 21.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +40.4% over the last 4 quarters against +17.3%/yr over the last 8 — accelerating; TTM profit +50.2% vs +47.9%/yr — stabilising.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Rashi Peripherals Ltd's operating margin is 3.0% in the Jun 26 quarter, −0.3 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 1.5% to 3.6%. The current quarter sits inside that band.
The latest quarter's operating margin is 3.0%, −0.3 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 1.5%–3.6%.
🚨 Why the margin moved: operating margin went −0.2 pp year on year while gross margin went −1.0 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Rashi Peripherals Ltd earned ₹105 Cr of net profit in the Jun 26 quarter, +69.4% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹282 Cr. The 7-year compound rate is 38.4%. That is 2.1% of the quarter's revenue. The same quarter a year earlier earned ₹62.0 Cr.
Jun 26 profit was ₹105 Cr, +69.4% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹282 Cr (+34.3%), and the 7-year compound rate is 38.4%.
Why profit moved: revenue contributed +61.9% and the margin −0.3 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +63.1% vs revenue +41.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years −45% of Rashi Peripherals Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹114 Cr of operating cash against ₹282 Cr of profit. After ₹39.0 Cr of capital spending, ₹75.0 Cr was left as free cash.
FY26: operating cash of ₹114 Cr against reported profit of ₹282 Cr, leaving free cash of ₹75.0 Cr after ₹39.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −45% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −45%: the cash cycle stretched 17 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 17 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Rashi Peripherals Ltd's cash conversion cycle runs 60 days in FY26, up from 43 days in FY21. Capital spending ran ₹57.0 Cr over the last 3 years. At FY26 sales of ₹15,827 Cr each day of that cycle holds about ₹43.4 Cr, so roughly ₹2,602 Cr sits inside the business at any moment.
FY26: debtors at 50 days, inventory at 62 days — roughly 2.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 60 days, looser than FY21's 43.
The full loop: cash goes out to suppliers and production on day 0; stock waits 62 days to sell; customers pay about 50 days after that; and suppliers themselves are paid at 53 days — netting out to the 60-day cycle.
In money terms: at FY26 sales of ₹15,827 Cr, each day of the cycle holds about ₹43.4 Cr — so the 60-day loop keeps roughly ₹2,602 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹57.0 Cr over the last 3 fiscal years against ₹58.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Rashi Peripherals Ltd earns a ROCE of 17% in FY26. That is up from a trough of 14% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 1.8% net margin on 2.97× asset turns.
FY26 ROCE is 17%, recovered from a FY24 trough of 14% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 1.8% net margin × 2.97× asset turns × 2.63× balance-sheet leverage ≈ 14.1% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 17% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Rashi Peripherals Ltd carries ₹991 Cr of borrowings against ₹2,025 Cr of equity in FY26, a debt-to-equity of 0.49. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹490 Cr to ₹991 Cr. Capital spending ran ₹57.0 Cr across the last 3 of those years.
FY26: borrowings of ₹991 Cr against equity of ₹2,025 Cr — a debt-to-equity of 0.49. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹490 Cr to ₹991 Cr while capital spending ran ₹57.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 17% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 3.5 points of Rashi Peripherals Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 12.7% of the company. Foreign institutions moved +1.9 points over the same window, to 3.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −3.5 points over 8 quarters to 12.7%; Foreign institutions: +1.9 points over 8 quarters to 3.3%; Promoters: +0.6 points over 8 quarters to 64.0%.
Why the register moved: rotation — foreign institutions +1.9 points against domestic institutions −3.5 points over 8 quarters, with promoters +0.6 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Rashi Peripherals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Nupur Recyclers LtdNRL | 67.5/100Favorable setup87% evidence | LEADER | 22.2/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.6/25 ROCE 15.1% · OPM 11.6% 95% evidence | 8.8/20 P/E 65.1× · PEG — 50% evidence | 19.9/20 RS sector 91.7% · RS bench 122% · 1Y 108.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 16.6 + 8.8 + 19.9 = 67.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Magnus Steel & Infra Ltd517320 | 67.2/100Thin evidence · provisional56% evidence | 27.5/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 46.1% · 1Y 1238.7%11 of 12 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.5 + 18.5 + 9.2 + 12 = 67.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Vision Infra Equipment Solutions LtdVIESL | 66.5/100Thin evidence · provisional56% evidence | BREAKING OUT | 18.9/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.9/25 ROCE 22.6% · OPM 26% 95% evidence | 10.9/20 P/E 14× · PEG — 15% evidence | 16.8/20 RS sector 14.5% · RS bench 34.1% · 1Y 52.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 19.9 + 10.9 + 16.8 = 66.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Rashi Peripherals Ltdthis pageRPTECH | 63.3/100Mixed-positive evidence75% evidence | LEADER | 24.3/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 17% · OPM 3% 76% evidence | 10.6/20 P/E 18.6× · PEG — 15% evidence | 13.7/20 RS sector 55.9% · RS bench 78.7% · 1Y 180.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 14.7 + 10.6 + 13.7 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shankara Buildpro LtdBUILDPRO | 62.8/100Mixed-positive evidence63% evidence | BREAKING OUT | 25.1/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.4/25 ROCE 39% · OPM 3.2% 100% evidence | 10.3/20 P/E 23.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 12 weeks ahead 0% evidence |
| Exact sum: 25.1 + 17.4 + 10.3 + 10 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Pramara Promotions LtdPRAMARA | 61.7/100Mixed-positive evidence69% evidence | 22.3/35 Revenue 72.7% · PAT 100% · OPM change 1 pp 59% evidence | 14.3/25 ROCE 15% · OPM 14.6% 95% evidence | 14.4/20 P/E 14.2× · PEG — 50% evidence | 10.7/20 RS sector 7.9% · RS bench -60.1% · 1Y -62.9%10 of 12 weeks ahead 70% evidence | |
| Exact sum: 22.3 + 14.3 + 14.4 + 10.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Tembo Global Industries LtdTEMBO | 61.4/100Mixed-positive evidence80% evidence | TURNING | 21.7/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.5/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 10.6× · PEG — 15% evidence | 9.9/20 RS sector -15.7% · RS bench 0.5% · 1Y -4.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 18.5 + 11.3 + 9.9 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Arisinfra Solutions LtdARIS | 58.5/100Mixed-positive evidence65% evidence | BREAKING OUT | 21.7/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.1/25 ROCE 15.6% · OPM 11% 95% evidence | 10.6/20 P/E 17.4× · PEG — 15% evidence | 11.1/20 RS sector — · RS bench 12.5% · 1Y -12.1%6 of 11 weeks ahead 25% evidence |
| Exact sum: 21.7 + 15.1 + 10.6 + 11.1 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Ivalue Infosolutions LtdIVALUE | 58.5/100Mixed-positive evidence65% evidence | ASLEEP | 20.2/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.6/25 ROCE 25.4% · OPM 10% 95% evidence | 11.2/20 P/E 11.1× · PEG — 15% evidence | 8.5/20 RS sector — · RS bench -11.3% · 1Y -18.7%5 of 11 weeks ahead 25% evidence |
| Exact sum: 20.2 + 18.6 + 11.2 + 8.5 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Mangalam Global Enterprise LtdMGEL | 58.4/100Mixed-positive evidence80% evidence | 25.1/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 15.9/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 6.3/20 RS sector -15% · RS bench -0.2% · 1Y -6.2%4 of 5 weeks ahead to 2026-08-09 100% evidence | |
| Exact sum: 25.1 + 15.9 + 11.1 + 6.3 = 58.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -15% and the one-year return is -6.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 11Euro Pratik Sales LtdEUROPRATIK | 57.7/100Mixed-positive evidence78% evidence | ASLEEP | 14.9/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.4/25 ROCE 36.9% · OPM 26% 100% evidence | 15.2/20 P/E 25.3× · PEG 0.62 65% evidence | 8.2/20 RS sector — · RS bench -20.6% · 1Y -9.2%5 of 11 weeks ahead 25% evidence |
| Exact sum: 14.9 + 19.4 + 15.2 + 8.2 = 57.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Singer India LtdSINGERIND | 57.3/100Thin evidence · provisional52% evidence | 26.1/35 Revenue 43.5% · PAT 100% · OPM change 6.5 pp 71% evidence | 10.2/25 ROCE 10.9% · OPM 2.5% 76% evidence | 10.1/20 P/E 25.9× · PEG — 15% evidence | 10.9/20 RS sector — · RS bench 9.7% · 1Y — 25% evidence | |
| Exact sum: 26.1 + 10.2 + 10.1 + 10.9 = 57.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 56.7/100Thin evidence · provisional54% evidence | BREAKING OUT | 21.0/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.1/25 ROCE 18.9% · OPM 6% 76% evidence | 8.8/20 P/E 253× · PEG — 15% evidence | 13.8/20 RS sector -0.7% · RS bench 17.3% · 1Y 35.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 13.1 + 8.8 + 13.8 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Sudarshan Pharma Industries Ltd543828 | 56.4/100Mixed-positive evidence82% evidence | FADING | 20.5/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.7/25 ROCE 15.1% · OPM 9.1% 76% evidence | 8.5/20 P/E 38.2× · PEG — 50% evidence | 13.7/20 RS sector 11.1% · RS bench 29.7% · 1Y 32.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 13.7 + 8.5 + 13.7 = 56.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Lloyds Enterprises LtdLLOYDSENT | 55.0/100Mixed-positive evidence75% evidence | TURNING | 18.0/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.2/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 107× · PEG — 15% evidence | 16.7/20 RS sector 6.1% · RS bench 24.9% · 1Y 19.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.2 + 9.1 + 16.7 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Onix Solar Energy LtdONIXSOLAR | 54.8/100Mixed-positive evidence69% evidence | 20.6/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 11.7/25 ROCE 11.3% · OPM 30% 76% evidence | 10.1/20 P/E 27.5× · PEG — 15% evidence | 12.4/20 RS sector 68.4% · RS bench -25.8% · 1Y 19.8%12 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.6 + 11.7 + 10.1 + 12.4 = 54.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Patel Retail LtdPATELRMART | 53.2/100Mixed-positive evidence65% evidence | FADING | 17.9/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.3/25 ROCE 15.3% · OPM 6.1% 95% evidence | 10.7/20 P/E 16.6× · PEG — 15% evidence | 10.3/20 RS sector — · RS bench 2.1% · 1Y -12.3%4 of 11 weeks ahead 25% evidence |
| Exact sum: 17.9 + 14.3 + 10.7 + 10.3 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Prostarm Info Systems LtdPROSTARM | 51.8/100Mixed-positive evidence65% evidence | TURNING | 16.6/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence | 16.0/25 ROCE 18% · OPM 8.5% 95% evidence | 10.4/20 P/E 22.7× · PEG — 15% evidence | 8.8/20 RS sector — · RS bench -4.7% · 1Y -31.9%0 of 11 weeks ahead 25% evidence |
| Exact sum: 16.6 + 16 + 10.4 + 8.8 = 51.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Pervasive Commodities Ltd517172 | 51.0/100Thin evidence · provisional52% evidence | TURNING | 16.6/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence | 14.4/25 ROCE 22.1% · OPM -10.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 2 weeks ahead 0% evidence |
| Exact sum: 16.6 + 14.4 + 10 + 10 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Fabtech Technologies LtdFABTECH | 50.9/100Thin evidence · provisional52% evidence | ASLEEP | 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.4/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.0/20 P/E 13.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -25.2%0 of 11 weeks ahead 0% evidence |
| Exact sum: 17.5 + 12.4 + 11 + 10 = 50.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21BMW Ventures LtdBMW | 49.8/100Thin evidence · provisional55% evidence | 16.7/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 12.0/25 ROCE 12% · OPM 3.4% 76% evidence | 11.1/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead to 2026-08-23 0% evidence | |
| Exact sum: 16.7 + 12 + 11.1 + 10 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Yogi LtdYOGI | 48.8/100Thin evidence · provisional58% evidence | 20.1/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 10.1/25 ROCE 12.8% · OPM 2.6% 76% evidence | 9.4/20 P/E 55.5× · PEG — 15% evidence | 9.2/20 RS sector -6.5% · RS bench 2.3% · 1Y -4.3%2 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.1 + 10.1 + 9.4 + 9.2 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Bizotic Commercial Ltd543926 | 48.6/100Thin evidence · provisional58% evidence | BASING | 19.7/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.7/25 ROCE 26.8% · OPM 8% 76% evidence | 9.3/20 P/E 36.6× · PEG — 50% evidence | 0.9/20 RS sector -85.7% · RS bench -11.9% · 1Y -76.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 18.7 + 9.3 + 0.9 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24SG Mart LtdSGMART | 48.3/100Mixed-negative evidence93% evidence | LEADER | 13.7/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence | 8.4/25 ROCE 10.2% · OPM 4.5% 100% evidence | 8.2/20 P/E 74.1× · PEG 1.92 65% evidence | 18.0/20 RS sector 25.9% · RS bench 45.7% · 1Y 91.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.7 + 8.4 + 8.2 + 18 = 48.3 · Decision use: Price leads the evidence: RS versus the benchmark is 45.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25Shiv Aum Steels LtdSHIVAUM | 47.6/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.8/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 7.3/20 P/E 73.2× · PEG — 50% evidence | 12.1/20 RS sector — · RS bench 49.9% · 1Y —8 of 8 weeks ahead 25% evidence |
| Exact sum: 16.8 + 11.4 + 7.3 + 12.1 = 47.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26State Trading Corporation of India LtdSTCINDIA | 46.7/100Thin evidence · provisional57% evidence | ASLEEP | 22.8/35 Revenue — · PAT 100% · OPM change — 57% evidence | 7.6/25 ROCE 7.6% · OPM — 80% evidence | 10.8/20 P/E 15.6× · PEG — 15% evidence | 5.5/20 RS sector -28.7% · RS bench -6.8% · 1Y -11.5%1 of 12 weeks ahead 70% evidence |
| Exact sum: 22.8 + 7.6 + 10.8 + 5.5 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Dhunseri Ventures LtdDVL | 46.6/100Mixed-negative evidence87% evidence | BREAKING OUT | 12.5/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.4/25 ROCE 6.7% · OPM 39% 95% evidence | 11.9/20 P/E 5.3× · PEG — 50% evidence | 12.8/20 RS sector -6.5% · RS bench 11.7% · 1Y -19.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.5 + 9.4 + 11.9 + 12.8 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28MMTC LtdMMTC | 42.3/100Mixed-negative evidence96% evidence | ASLEEP | 15.0/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 7.8/25 ROCE 8.7% · OPM — 84% evidence | 15.6/20 P/E 43.5× · PEG 0.92 100% evidence | 3.9/20 RS sector -21% · RS bench -6.1% · 1Y -13.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 7.8 + 15.6 + 3.9 = 42.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 29Hexa Tradex LtdHEXATRADEX | 41.7/100Mixed-negative evidence65% evidence | TURNING | 17.0/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.2/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.5/20 RS sector -17.1% · RS bench -1.3% · 1Y -11.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 6.2 + 10 + 8.5 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Cropster Agro Ltd523105 | 41.1/100Mixed-negative evidence69% evidence | ASLEEP | 15.3/35 Revenue 28.4% · PAT 6.5% · OPM change 1.7 pp 95% evidence | 11.7/25 ROCE 12.4% · OPM 9.8% 76% evidence | 10.8/20 P/E 15.6× · PEG — 15% evidence | 3.3/20 RS sector -72.7% · RS bench -73.3% · 1Y -86.8%0 of 4 weeks ahead 70% evidence |
| Exact sum: 15.3 + 11.7 + 10.8 + 3.3 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Adani Enterprises LtdADANIENT | 41.0/100Mixed-negative evidence93% evidence | ASLEEP | 14.1/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.3/25 ROCE 5.8% · OPM 15% 100% evidence | 7.6/20 P/E 166× · PEG 1.96 65% evidence | 11.0/20 RS sector 1% · RS bench 18.4% · 1Y 19.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 8.3 + 7.6 + 11 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32RRP Semiconductor LtdRRP | 40.9/100Thin evidence · provisional54% evidence | 11.2/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.6/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.1/20 RS sector 65.3% · RS bench 0.8% · 1Y 36.6%0 of 1 week ahead to 2026-08-23 70% evidence | |
| Exact sum: 11.2 + 5.6 + 10 + 14.1 = 40.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Le Merite Exports LtdLEMERITE | 40.1/100Thin evidence · provisional57% evidence | 18.0/35 Revenue — · PAT — · OPM change -15.5 pp 45% evidence | 6.8/25 ROCE 9.9% · OPM -10.7% 95% evidence | 9.1/20 P/E 94.5× · PEG — 15% evidence | 6.2/20 RS sector -9% · RS bench -68.5% · 1Y -94.7%0 of 2 weeks ahead 70% evidence | |
| Exact sum: 18 + 6.8 + 9.1 + 6.2 = 40.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Blue Pearl Agriventures LtdBPAGRI | 39.2/100Mixed-negative evidence69% evidence | 20.0/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.2/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -88.6%1 of 12 weeks ahead to 2026-08-23 70% evidence | |
| Exact sum: 20 + 6.2 + 8.7 + 4.3 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Riddhi Siddhi Gluco Biols Ltd524480 | 39.0/100Mixed-negative evidence82% evidence | FADING | 12.4/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence | 6.5/25 ROCE 2.7% · OPM -3% 76% evidence | 6.3/20 P/E 37.4× · PEG — 50% evidence | 13.8/20 RS sector 7.8% · RS bench 25.9% · 1Y 28.1%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 6.5 + 6.3 + 13.8 = 39 · Decision use: Price leads the evidence: RS versus the benchmark is 25.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 36Hardwyn India LtdHARDWYN | 38.7/100Mixed-negative evidence87% evidence | ASLEEP | 13.5/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.3/25 ROCE 4.8% · OPM 13% 95% evidence | 11.1/20 P/E 51.2× · PEG — 50% evidence | 1.8/20 RS sector -38.8% · RS bench -27.7% · 1Y -3.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 13.5 + 12.3 + 11.1 + 1.8 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Neueon Corporation LtdNEUEON | 37.6/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.9/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.6/20 RS sector 12.7% · RS bench 16.3% · 1Y —0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.9 + 10 + 14.6 = 37.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38PTC India LtdPTC | 36.6/100Mixed-negative evidence82% evidence | BASING | 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.7/25 ROCE 13.4% · OPM 3.1% 76% evidence | 8.9/20 P/E 9× · PEG — 50% evidence | 3.8/20 RS sector -21.7% · RS bench -7.2% · 1Y -11.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 12.7 + 8.9 + 3.8 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Kothari Industrial Corporation LtdKOTIC | 34.3/100Adverse evidence63% evidence | BASING | 18.7/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 1.7/25 ROCE -28.9% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.9/20 RS sector -58.6% · RS bench -33.2% · 1Y -71.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 18.7 + 1.7 + 10 + 3.9 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40BN Agrochem LtdBNAGROCHEM | 32.1/100Adverse evidence77% evidence | BASING | 12.8/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.2/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.0/20 P/E 119× · PEG — 15% evidence | 6.1/20 RS sector -16.7% · RS bench -26.3% · 1Y -40.5%4 of 12 weeks ahead 70% evidence |
| Exact sum: 12.8 + 4.2 + 9 + 6.1 = 32.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Shanti Overseas (India) LtdSHANTI | 32.0/100Thin evidence · provisional56% evidence | 11.3/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.7/25 ROCE -25.2% · OPM -216.5% 71% evidence | 12.4/20 P/E 3× · PEG — 50% evidence | 3.6/20 RS sector -60.4% · RS bench -49.7% · 1Y -45.6%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.3 + 4.7 + 12.4 + 3.6 = 32 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Uniphos Enterprises LtdUNIENTER | 29.8/100Adverse evidence69% evidence | ASLEEP | 12.3/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.5/25 ROCE 0.8% · OPM — 80% evidence | 8.3/20 P/E 30.9× · PEG — 50% evidence | 4.7/20 RS sector -43.6% · RS bench -20.6% · 1Y -42.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 12.3 + 4.5 + 8.3 + 4.7 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 43Oswal Agro Mills LtdOSWALAGRO | 24.7/100Adverse evidence67% evidence | BASING | 2.9/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.7/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -50.3% · RS bench -30.3% · 1Y -55.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 2.9 + 7.7 + 10 + 4.1 = 24.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Susan Electricals India Ltd544793 | 58.9/100Thin evidence · provisional31% evidence | 20.6/35 Revenue — · PAT — · OPM change 7.8 pp 26% evidence | 18.1/25 ROCE 37% · OPM 11.9% 76% evidence | 10.2/20 P/E 23.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 20.6 + 18.1 + 10.2 + 10 = 58.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Q-Line Biotech LtdQLINE | 57.7/100Thin evidence · provisional31% evidence | TURNING | 17.9/35 Revenue — · PAT — · OPM change 10 pp 13% evidence | 19.8/25 ROCE 22.5% · OPM 31% 95% evidence | 10.0/20 P/E 27.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 17.9 + 19.8 + 10 + 10 = 57.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46DC Infotech & Communication LtdDCI | 57.5/100Thin evidence · provisional35% evidence | TURNING | 18.4/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence | 17.7/25 ROCE 22.9% · OPM 4.7% 76% evidence | 10.4/20 P/E 22.7× · PEG — 15% evidence | 11.0/20 RS sector — · RS bench 10.5% · 1Y —1 of 1 week ahead 25% evidence |
| Exact sum: 18.4 + 17.7 + 10.4 + 11 = 57.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Mardia Samyoung Capillary Tubes Company LtdMSCTC | 57.0/100Thin evidence · provisional32% evidence | 20.9/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.3/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 74.6% · 1Y 59.1%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.9 + 15.3 + 8.6 + 12.2 = 57 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Proventus Agrocom LtdPROV | 56.5/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.5/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.7/25 ROCE 11.5% · OPM 1.8% 95% evidence | 12.5/20 P/E 47.8× · PEG — 50% evidence | 11.8/20 RS sector — · RS bench 39.7% · 1Y —12 of 12 weeks ahead 25% evidence |
| Exact sum: 19.5 + 12.7 + 12.5 + 11.8 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49SK Minerals & Additives Ltd544584 | 55.5/100Thin evidence · provisional36% evidence | BREAKING OUT | 16.5/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 19.1/25 ROCE 26.2% · OPM 10.7% 76% evidence | 9.9/20 P/E 29.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 6 weeks ahead 0% evidence |
| Exact sum: 16.5 + 19.1 + 9.9 + 10 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 50Arvaya Healthcare LtdARVAYA | 54.7/100Thin evidence · provisional19% evidence | 18.6/35 Revenue — · PAT — · OPM change 46.1 pp 10% evidence | 12.3/25 ROCE — · OPM 13% 30% evidence | 11.4/20 P/E 3.9× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 104.2% · 1Y — 25% evidence | |
| Exact sum: 18.6 + 12.3 + 11.4 + 12.4 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 51Monika Alcobev LtdMONIKA | 53.9/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.5/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -19.3%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.5 + 10 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 52Shah Foods Ltd519031 | 53.5/100Thin evidence · provisional18% evidence | BREAKING OUT | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.9/20 P/E 246× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 75.6% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 17.1 + 15.3 + 8.9 + 12.2 = 53.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 53Manbro Industries Ltd512595 | 51.0/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.2/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.5/20 RS sector -17.3% · RS bench 37.2% · 1Y 75.3%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.2 + 10 + 9.5 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 54Satani Bearings Ltd505703 | 45.2/100Thin evidence · provisional38% evidence | TURNING | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.7/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5287× · PEG — 15% evidence | 11.4/20 RS sector — · RS bench 24.6% · 1Y 181.4%3 of 11 weeks ahead 25% evidence |
| Exact sum: 20.5 + 4.7 + 8.6 + 11.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Keto Motors Ltd537392 | 43.2/100Thin evidence · provisional38% evidence | BREAKING OUT | 16.2/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 7722× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 241.5% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 16.2 + 6 + 8.5 + 12.5 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 56A-1 LtdA1L | 41.0/100Thin evidence · provisional50% evidence | 16.1/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.7/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.7/20 P/E 383× · PEG — 15% evidence | 5.5/20 RS sector -24.5% · RS bench -16% · 1Y -10.6%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.1 + 10.7 + 8.7 + 5.5 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Aerpace Industries Ltd534733 | 40.5/100Thin evidence · provisional32% evidence | 13.0/35 Revenue — · PAT -80% · OPM change — 33% evidence | 5.6/25 ROCE -21.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.9/20 RS sector — · RS bench 44% · 1Y — 25% evidence | |
| Exact sum: 13 + 5.6 + 10 + 11.9 = 40.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Prabhatam Infra Venture LtdPRABHATAM | 39.2/100Thin evidence · provisional22% evidence | 16.1/35 Revenue — · PAT -80% · OPM change — 8% evidence | 3.1/25 ROCE -97.1% · OPM -23.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.1 + 3.1 + 10 + 10 = 39.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Rashi Peripherals Ltd's share price today?
Rashi Peripherals Ltd trades at ₹893, +183.1% over the past year. The company is valued at ₹5,930 Cr. The stock sits at the very top of its 52-week range (₹325–₹895), +45.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 47 weeks in. — as of 25 September 2026.
What were Rashi Peripherals Ltd's latest quarterly results?
Rashi Peripherals Ltd reported revenue of ₹5,102 Cr and net profit of ₹105 Cr for the Jun 26 quarter. Revenue rose 61.9% and profit rose 69.4% year on year. Earnings per share were ₹15.59. The operating margin was 3.0%, 0.3 pp lower than a year earlier. — as of 25 September 2026.
What is Rashi Peripherals Ltd's revenue?
Rashi Peripherals Ltd reported revenue of ₹5,102 Cr in the Jun 26 quarter, +61.9% year on year. For the full FY26 fiscal year, revenue was ₹15,827 Cr (+14.9%). Over the last 7 years revenue compounded at 21.8% a year. — as of 25 September 2026.
What is Rashi Peripherals Ltd's profit?
Rashi Peripherals Ltd earned ₹105 Cr of net profit in the Jun 26 quarter, +69.4% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹282 Cr. The operating margin ran 3.0% in the latest quarter. — as of 25 September 2026.
What is Rashi Peripherals Ltd's market cap?
Rashi Peripherals Ltd's market capitalisation is ₹5,930 Cr at a share price of ₹893. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 25 September 2026.
What is Rashi Peripherals Ltd's P/E ratio?
Rashi Peripherals Ltd trades at a P/E of 18.6×, at the 93rd percentile of its own 2-year range, against a long-run median of 10.8×. This is a comparison with the stock's own history, not a value call — as of 25 September 2026.
Does Rashi Peripherals Ltd pay a dividend?
Yes — Rashi Peripherals Ltd's dividend payout was 5% of profit in FY26, and it recorded a payout in 4 of its last 8 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 25 September 2026.
Is Rashi Peripherals Ltd overvalued?
On its own history, Rashi Peripherals Ltd looks expensive: its P/E of 18.6× sits at the 93rd percentile of its 2-year range (long-run median 10.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 25 September 2026.
Is Rashi Peripherals Ltd growing?
Yes — Rashi Peripherals Ltd is growing: latest-quarter revenue +61.9% year on year, profit +69.4%, and the margin −0.3 pp at 3.0%. The 7-year compound rates are 21.8% (revenue) and 38.4% (profit). The earnings engine currently reads: improving — as of 25 September 2026.
How is Rashi Peripherals Ltd performing?
Rashi Peripherals Ltd is in a confirmed uptrend, 47 weeks in. Its latest quarter's revenue rose 61.9% and profit rose 69.4% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 60 weeks. This describes what the data did, not a rating. — as of 25 September 2026.
What stage is Rashi Peripherals Ltd in?
Consistent — revenue and profit growth have stayed positive through the window, with ROCE at 17.0% and holding. The read comes from the last 12 quarters of growth (revenue growth +40.4% latest, profit growth +50.2% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 25 September 2026.
Is Rashi Peripherals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 47 of stage 2), trading +45.7% versus its 200-day average and at the very top of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 25 September 2026.
Is Rashi Peripherals Ltd beating the market?
On recent form, yes — Rashi Peripherals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 60 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.6 years the stock moved +158% against the NIFTY 500's +12% — ahead of the index over the full window. — as of 25 September 2026.
Will Rashi Peripherals Ltd's share price go up?
This page publishes no price forecast for Rashi Peripherals Ltd. What it measures instead: the share price is ₹893, the price is in a confirmed uptrend 47 weeks in. Its P/E of 18.6× sits at the 93rd percentile of its own 2-year range. — as of 25 September 2026.
Who owns Rashi Peripherals Ltd?
Promoters hold 64.0% of Rashi Peripherals Ltd, foreign institutions 3.3%, domestic institutions 12.7% and the public 20.0% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 3.5 points over 8 quarters. — as of 25 September 2026.
Does Rashi Peripherals Ltd have too much debt?
It is moderate — Rashi Peripherals Ltd's debt-to-equity is 0.49, and operating profit covers the interest bill 4×. FY26 borrowings were ₹991 Cr against equity of ₹2,025 Cr. Read the returns on this page with that leverage in mind — as of 25 September 2026.
What is Rashi Peripherals Ltd's capex?
Rashi Peripherals Ltd spent ₹57.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹39.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 25 September 2026.
What is Rashi Peripherals Ltd's cash flow?
Rashi Peripherals Ltd generated ₹114 Cr of operating cash flow in FY26 and ₹75.0 Cr of free cash flow after ₹39.0 Cr of capital spending. Reported profit that year was ₹282 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 25 September 2026.
Is Rashi Peripherals Ltd's profit real cash?
No — operating cash was negative over the last 3 fiscal years: Rashi Peripherals Ltd consumed cash while reporting profit. In FY26, operating cash was ₹114 Cr against reported profit of ₹282 Cr. Cash-flow resolution is annual — as of 25 September 2026.
Where is Rashi Peripherals Ltd in its business cycle?
Rashi Peripherals Ltd's FY26 operating margin was 2.9%, against a 8-year band of 1.5%–3.6%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 3.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 25 September 2026.
What growth does Rashi Peripherals Ltd's price assume?
At its price on 13 June 2026, Rashi Peripherals Ltd was priced for profit growth of about 4.2% a year. Profit itself has compounded 38.4% a year over the past 7 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 25 September 2026.
What could break the Rashi Peripherals Ltd story?
The sharpest disagreement: profits are rising, but only −45% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 25 September 2026.
Is Rashi Peripherals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Rashi Peripherals Ltd's price has outrun its earnings. +183.1% in a year against EPS +33.4% — the market is paying now for delivery later. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 25 September 2026.
Not SEBI Registered !! Not Investment advice !!